Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01437046 · ClinicalTrials.gov registry record · Early Phase 1
Doxazosin an a1 Antagonist for Alcohol Dependence
A Early Phase 1 study, sponsored by Brown University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 41
- Enrollment target
NCT01437046 is a Early Phase 1 study that has completed, run by Brown University. The registered enrollment target is 41 participants.
The verdict
NCT01437046, a Early Phase 1 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. The α1 -blocker doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been studied for AD. A double-blind placebo-controlled randomized clinical trial was designed in AD individuals seeking outpatient treatment. Doxazosin or matched placebo was titrated to 16 mg/day (or maximum tolerable dose). Drinks per week (DPW) and heavy drinking days (HDD) per week were the primary outcomes. Family history density of alcoholism (FHDA), severity of AD and gender were a priori moderators.
Interventions
- DRUG Placebo
- DRUG Doxazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-11-01 |
| Est. Completion | 2015-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01437046
The ClinicalTrials.gov registry entry for NCT01437046 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01437046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01437046 about?
NCT01437046 is a clinical study titled "Doxazosin an a1 Antagonist for Alcohol Dependence". Norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. The α1 -blocker doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been stu...
What is the current status of trial NCT01437046?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 41 participants. The study started on 2011-11-01. Estimated completion is 2015-03-01.
What interventions are being tested in trial NCT01437046?
The interventions under investigation include: Placebo (DRUG), Doxazosin (DRUG).
Who is sponsoring clinical trial NCT01437046?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.